...
首页> 外文期刊>Journal of Medicinal Chemistry >Novel Human Aminopeptidase N Inhibitors: Discovery and Optimization of Subsite Binding Interactions
【24h】

Novel Human Aminopeptidase N Inhibitors: Discovery and Optimization of Subsite Binding Interactions

机译:新型人氨基肽酶N抑制剂:底座结合相互作用的发现和优化

获取原文
获取原文并翻译 | 示例
           

摘要

Aminopeptidase N (APN/CD13) is a zinc-dependent M1 aminopeptidase that contributes to cancer progression by promoting angiogenesis, metastasis, and tumor invasion. We have previously identified hydroxamic acid-containing analogues that are potent inhibitors of the APN homologue from the malarial parasite Plasmodium falciparum M1 aminopeptidase (PfA-M1). Herein, we describe the rationale that underpins the repurposing of PfA-MI inhibitors as novel APN inhibitors. A series of novel hydroxamic acid analogues were developed using a structure-based design approach and evaluated their inhibition activities against APN. N-(2-(Hydroxyamino)-2-oxo-1-(3',4',5'-trifluoro-[1,1'-biphenyl]-4-yOethyl)-4(methylsulfonamido)benzamide (6ad) proved to be an extremely potent inhibitor of APN activity in vitro, selective against other zinc-dependent enzymes such as matrix metalloproteases, and possessed limited cytotoxicity against Ad293 cells and favorable physicochemical and metabolic stability properties. The combined results indicate that compound 6ad may be a useful lead for the development of anticancer agents.
机译:氨肽酶N(APN / CD13)是锌依赖性M1氨基肽酶,其通过促进血管生成,转移和肿瘤侵袭有助于癌症进展。我们先前鉴定了含异羟肟酸的类似物,其是来自疟原虫寄生虫疟原虫M1氨基肽酶(PFA-M1)的APN同源物的有效抑制剂。在此,我们描述了基础抑制PFA-MI抑制剂作为新型APN抑制剂的理由。使用基于结构的设计方法开发了一系列新的羟肟酸类似物,并评估了对APN的抑制作用。 N-(2-(羟基氨基)-2-氧代-1-(3',4',5'-三氟-[1,1'-Biphenyl] -4- yo乙基)-4(甲基磺酰氨基)苯甲酰胺(6AD)证明作为体外的APN活性的极其有效的抑制剂,对诸如基质金属蛋白酶的其他锌依赖性酶选择,并且具有针对AD293细胞的有限细胞毒性,并且有利的物理化学和代谢稳定性。组合结果表明化合物6AD可能是一种有用的领导抗癌剂的发展。

著录项

  • 来源
    《Journal of Medicinal Chemistry》 |2019年第15期|共25页
  • 作者单位

    Monash Univ Monash Inst Pharmaceut Sci Med Chem Parkville Campus Parkville Vic 3052 Australia;

    Monash Univ Monash Inst Pharmaceut Sci Med Chem Parkville Campus Parkville Vic 3052 Australia;

    Monash Univ Infect &

    Immun Program Biomed Discovery Inst Clayton Campus Clayton Vic 3800 Australia;

    Monash Univ Infect &

    Immun Program Biomed Discovery Inst Clayton Campus Clayton Vic 3800 Australia;

    Monash Univ Infect &

    Immun Program Biomed Discovery Inst Clayton Campus Clayton Vic 3800 Australia;

    Monash Univ Monash Inst Pharmaceut Sci Med Chem Parkville Campus Parkville Vic 3052 Australia;

    Monash Univ Monash Inst Pharmaceut Sci Med Chem Parkville Campus Parkville Vic 3052 Australia;

    Univ British Columbia Life Sci Inst Dept Biochem &

    Mol Biol Vancouver BC V6T 1Z3 Canada;

    Univ British Columbia Life Sci Inst Dept Biochem &

    Mol Biol Vancouver BC V6T 1Z3 Canada;

    Univ British Columbia Life Sci Inst Dept Biochem &

    Mol Biol Vancouver BC V6T 1Z3 Canada;

    Monash Univ Monash Inst Pharmaceut Sci Ctr Drug Candidate Optimisat Parkville Campus Parkville Vic 3052 Australia;

    Monash Univ Infect &

    Immun Program Biomed Discovery Inst Clayton Campus Clayton Vic 3800 Australia;

    Monash Univ Monash Inst Pharmaceut Sci Med Chem Parkville Campus Parkville Vic 3052 Australia;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号